The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Epigenetics Drugs and Diagnostic Technologies Market Research Report 2025

Global Epigenetics Drugs and Diagnostic Technologies Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1892827

No of Pages : 105

Ask Your Query

Synopsis

The global Epigenetics Drugs and Diagnostic Technologies market was valued at US$ 9007.4 million in 2023 and is anticipated to reach US$ 27650 million by 2030, witnessing a CAGR of 17.1% during the forecast period 2024-2030.

North American market for Epigenetics Drugs and Diagnostic Technologies is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Epigenetics Drugs and Diagnostic Technologies is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for Epigenetics Drugs and Diagnostic Technologies in Non coding RNA’s is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of Epigenetics Drugs and Diagnostic Technologies include Varlix Plc, Topotarget, Syndax Pharmaceuticals, Spectrum Pharmaceuticals, Promega, Novartis, Oncolys BioPharma, MDxHealth and Merck, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Epigenetics Drugs and Diagnostic Technologies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Epigenetics Drugs and Diagnostic Technologies.

Report Scope

The Epigenetics Drugs and Diagnostic Technologies market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Epigenetics Drugs and Diagnostic Technologies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Epigenetics Drugs and Diagnostic Technologies companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company

  • Varlix Plc
  • Topotarget
  • Syndax Pharmaceuticals
  • Spectrum Pharmaceuticals
  • Promega
  • Novartis
  • Oncolys BioPharma
  • MDxHealth
  • Merck
  • Illumina
  • Epizyme
  • Forum Pharmaceuticals
  • EpiGentek
  • Chroma Therapeutics
  • Celleron Therapeutics
  • CellCentric
  • Astex Pharmaceuticals
  • Acetylon Pharmaceuticals
  • 4SC AG
  • Eisai
  • Pharmacyclics

Segment by Type

  • HDAC inhibitors
  • DNMT inhibitors

Segment by Application

  • Non coding RNA’s
  • Micro RNA’s
  • Histone modifications
  • DNA methylation

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Epigenetics Drugs and Diagnostic Technologies companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Epigenetics Drugs and Diagnostic Technologies Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 HDAC inhibitors
1.2.3 DNMT inhibitors
1.3 Market by Application
1.3.1 Global Epigenetics Drugs and Diagnostic Technologies Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Non coding RNA’s
1.3.3 Micro RNA’s
1.3.4 Histone modifications
1.3.5 DNA methylation
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Epigenetics Drugs and Diagnostic Technologies Market Perspective (2019-2030)
2.2 Epigenetics Drugs and Diagnostic Technologies Growth Trends by Region
2.2.1 Global Epigenetics Drugs and Diagnostic Technologies Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Epigenetics Drugs and Diagnostic Technologies Historic Market Size by Region (2019-2024)
2.2.3 Epigenetics Drugs and Diagnostic Technologies Forecasted Market Size by Region (2025-2030)
2.3 Epigenetics Drugs and Diagnostic Technologies Market Dynamics
2.3.1 Epigenetics Drugs and Diagnostic Technologies Industry Trends
2.3.2 Epigenetics Drugs and Diagnostic Technologies Market Drivers
2.3.3 Epigenetics Drugs and Diagnostic Technologies Market Challenges
2.3.4 Epigenetics Drugs and Diagnostic Technologies Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Epigenetics Drugs and Diagnostic Technologies Players by Revenue
3.1.1 Global Top Epigenetics Drugs and Diagnostic Technologies Players by Revenue (2019-2024)
3.1.2 Global Epigenetics Drugs and Diagnostic Technologies Revenue Market Share by Players (2019-2024)
3.2 Global Epigenetics Drugs and Diagnostic Technologies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Epigenetics Drugs and Diagnostic Technologies Revenue
3.4 Global Epigenetics Drugs and Diagnostic Technologies Market Concentration Ratio
3.4.1 Global Epigenetics Drugs and Diagnostic Technologies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Epigenetics Drugs and Diagnostic Technologies Revenue in 2023
3.5 Epigenetics Drugs and Diagnostic Technologies Key Players Head office and Area Served
3.6 Key Players Epigenetics Drugs and Diagnostic Technologies Product Solution and Service
3.7 Date of Enter into Epigenetics Drugs and Diagnostic Technologies Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Epigenetics Drugs and Diagnostic Technologies Breakdown Data by Type
4.1 Global Epigenetics Drugs and Diagnostic Technologies Historic Market Size by Type (2019-2024)
4.2 Global Epigenetics Drugs and Diagnostic Technologies Forecasted Market Size by Type (2025-2030)
5 Epigenetics Drugs and Diagnostic Technologies Breakdown Data by Application
5.1 Global Epigenetics Drugs and Diagnostic Technologies Historic Market Size by Application (2019-2024)
5.2 Global Epigenetics Drugs and Diagnostic Technologies Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Epigenetics Drugs and Diagnostic Technologies Market Size (2019-2030)
6.2 North America Epigenetics Drugs and Diagnostic Technologies Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Epigenetics Drugs and Diagnostic Technologies Market Size by Country (2019-2024)
6.4 North America Epigenetics Drugs and Diagnostic Technologies Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Epigenetics Drugs and Diagnostic Technologies Market Size (2019-2030)
7.2 Europe Epigenetics Drugs and Diagnostic Technologies Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Epigenetics Drugs and Diagnostic Technologies Market Size by Country (2019-2024)
7.4 Europe Epigenetics Drugs and Diagnostic Technologies Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Epigenetics Drugs and Diagnostic Technologies Market Size (2019-2030)
8.2 Asia-Pacific Epigenetics Drugs and Diagnostic Technologies Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Epigenetics Drugs and Diagnostic Technologies Market Size by Region (2019-2024)
8.4 Asia-Pacific Epigenetics Drugs and Diagnostic Technologies Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Epigenetics Drugs and Diagnostic Technologies Market Size (2019-2030)
9.2 Latin America Epigenetics Drugs and Diagnostic Technologies Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Epigenetics Drugs and Diagnostic Technologies Market Size by Country (2019-2024)
9.4 Latin America Epigenetics Drugs and Diagnostic Technologies Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Epigenetics Drugs and Diagnostic Technologies Market Size (2019-2030)
10.2 Middle East & Africa Epigenetics Drugs and Diagnostic Technologies Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Epigenetics Drugs and Diagnostic Technologies Market Size by Country (2019-2024)
10.4 Middle East & Africa Epigenetics Drugs and Diagnostic Technologies Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Varlix Plc
11.1.1 Varlix Plc Company Detail
11.1.2 Varlix Plc Business Overview
11.1.3 Varlix Plc Epigenetics Drugs and Diagnostic Technologies Introduction
11.1.4 Varlix Plc Revenue in Epigenetics Drugs and Diagnostic Technologies Business (2019-2024)
11.1.5 Varlix Plc Recent Development
11.2 Topotarget
11.2.1 Topotarget Company Detail
11.2.2 Topotarget Business Overview
11.2.3 Topotarget Epigenetics Drugs and Diagnostic Technologies Introduction
11.2.4 Topotarget Revenue in Epigenetics Drugs and Diagnostic Technologies Business (2019-2024)
11.2.5 Topotarget Recent Development
11.3 Syndax Pharmaceuticals
11.3.1 Syndax Pharmaceuticals Company Detail
11.3.2 Syndax Pharmaceuticals Business Overview
11.3.3 Syndax Pharmaceuticals Epigenetics Drugs and Diagnostic Technologies Introduction
11.3.4 Syndax Pharmaceuticals Revenue in Epigenetics Drugs and Diagnostic Technologies Business (2019-2024)
11.3.5 Syndax Pharmaceuticals Recent Development
11.4 Spectrum Pharmaceuticals
11.4.1 Spectrum Pharmaceuticals Company Detail
11.4.2 Spectrum Pharmaceuticals Business Overview
11.4.3 Spectrum Pharmaceuticals Epigenetics Drugs and Diagnostic Technologies Introduction
11.4.4 Spectrum Pharmaceuticals Revenue in Epigenetics Drugs and Diagnostic Technologies Business (2019-2024)
11.4.5 Spectrum Pharmaceuticals Recent Development
11.5 Promega
11.5.1 Promega Company Detail
11.5.2 Promega Business Overview
11.5.3 Promega Epigenetics Drugs and Diagnostic Technologies Introduction
11.5.4 Promega Revenue in Epigenetics Drugs and Diagnostic Technologies Business (2019-2024)
11.5.5 Promega Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Epigenetics Drugs and Diagnostic Technologies Introduction
11.6.4 Novartis Revenue in Epigenetics Drugs and Diagnostic Technologies Business (2019-2024)
11.6.5 Novartis Recent Development
11.7 Oncolys BioPharma
11.7.1 Oncolys BioPharma Company Detail
11.7.2 Oncolys BioPharma Business Overview
11.7.3 Oncolys BioPharma Epigenetics Drugs and Diagnostic Technologies Introduction
11.7.4 Oncolys BioPharma Revenue in Epigenetics Drugs and Diagnostic Technologies Business (2019-2024)
11.7.5 Oncolys BioPharma Recent Development
11.8 MDxHealth
11.8.1 MDxHealth Company Detail
11.8.2 MDxHealth Business Overview
11.8.3 MDxHealth Epigenetics Drugs and Diagnostic Technologies Introduction
11.8.4 MDxHealth Revenue in Epigenetics Drugs and Diagnostic Technologies Business (2019-2024)
11.8.5 MDxHealth Recent Development
11.9 Merck
11.9.1 Merck Company Detail
11.9.2 Merck Business Overview
11.9.3 Merck Epigenetics Drugs and Diagnostic Technologies Introduction
11.9.4 Merck Revenue in Epigenetics Drugs and Diagnostic Technologies Business (2019-2024)
11.9.5 Merck Recent Development
11.10 Illumina
11.10.1 Illumina Company Detail
11.10.2 Illumina Business Overview
11.10.3 Illumina Epigenetics Drugs and Diagnostic Technologies Introduction
11.10.4 Illumina Revenue in Epigenetics Drugs and Diagnostic Technologies Business (2019-2024)
11.10.5 Illumina Recent Development
11.11 Epizyme
11.11.1 Epizyme Company Detail
11.11.2 Epizyme Business Overview
11.11.3 Epizyme Epigenetics Drugs and Diagnostic Technologies Introduction
11.11.4 Epizyme Revenue in Epigenetics Drugs and Diagnostic Technologies Business (2019-2024)
11.11.5 Epizyme Recent Development
11.12 Forum Pharmaceuticals
11.12.1 Forum Pharmaceuticals Company Detail
11.12.2 Forum Pharmaceuticals Business Overview
11.12.3 Forum Pharmaceuticals Epigenetics Drugs and Diagnostic Technologies Introduction
11.12.4 Forum Pharmaceuticals Revenue in Epigenetics Drugs and Diagnostic Technologies Business (2019-2024)
11.12.5 Forum Pharmaceuticals Recent Development
11.13 EpiGentek
11.13.1 EpiGentek Company Detail
11.13.2 EpiGentek Business Overview
11.13.3 EpiGentek Epigenetics Drugs and Diagnostic Technologies Introduction
11.13.4 EpiGentek Revenue in Epigenetics Drugs and Diagnostic Technologies Business (2019-2024)
11.13.5 EpiGentek Recent Development
11.14 Chroma Therapeutics
11.14.1 Chroma Therapeutics Company Detail
11.14.2 Chroma Therapeutics Business Overview
11.14.3 Chroma Therapeutics Epigenetics Drugs and Diagnostic Technologies Introduction
11.14.4 Chroma Therapeutics Revenue in Epigenetics Drugs and Diagnostic Technologies Business (2019-2024)
11.14.5 Chroma Therapeutics Recent Development
11.15 Celleron Therapeutics
11.15.1 Celleron Therapeutics Company Detail
11.15.2 Celleron Therapeutics Business Overview
11.15.3 Celleron Therapeutics Epigenetics Drugs and Diagnostic Technologies Introduction
11.15.4 Celleron Therapeutics Revenue in Epigenetics Drugs and Diagnostic Technologies Business (2019-2024)
11.15.5 Celleron Therapeutics Recent Development
11.16 CellCentric
11.16.1 CellCentric Company Detail
11.16.2 CellCentric Business Overview
11.16.3 CellCentric Epigenetics Drugs and Diagnostic Technologies Introduction
11.16.4 CellCentric Revenue in Epigenetics Drugs and Diagnostic Technologies Business (2019-2024)
11.16.5 CellCentric Recent Development
11.17 Astex Pharmaceuticals
11.17.1 Astex Pharmaceuticals Company Detail
11.17.2 Astex Pharmaceuticals Business Overview
11.17.3 Astex Pharmaceuticals Epigenetics Drugs and Diagnostic Technologies Introduction
11.17.4 Astex Pharmaceuticals Revenue in Epigenetics Drugs and Diagnostic Technologies Business (2019-2024)
11.17.5 Astex Pharmaceuticals Recent Development
11.18 Acetylon Pharmaceuticals
11.18.1 Acetylon Pharmaceuticals Company Detail
11.18.2 Acetylon Pharmaceuticals Business Overview
11.18.3 Acetylon Pharmaceuticals Epigenetics Drugs and Diagnostic Technologies Introduction
11.18.4 Acetylon Pharmaceuticals Revenue in Epigenetics Drugs and Diagnostic Technologies Business (2019-2024)
11.18.5 Acetylon Pharmaceuticals Recent Development
11.19 4SC AG
11.19.1 4SC AG Company Detail
11.19.2 4SC AG Business Overview
11.19.3 4SC AG Epigenetics Drugs and Diagnostic Technologies Introduction
11.19.4 4SC AG Revenue in Epigenetics Drugs and Diagnostic Technologies Business (2019-2024)
11.19.5 4SC AG Recent Development
11.20 Eisai
11.20.1 Eisai Company Detail
11.20.2 Eisai Business Overview
11.20.3 Eisai Epigenetics Drugs and Diagnostic Technologies Introduction
11.20.4 Eisai Revenue in Epigenetics Drugs and Diagnostic Technologies Business (2019-2024)
11.20.5 Eisai Recent Development
11.21 Pharmacyclics
11.21.1 Pharmacyclics Company Detail
11.21.2 Pharmacyclics Business Overview
11.21.3 Pharmacyclics Epigenetics Drugs and Diagnostic Technologies Introduction
11.21.4 Pharmacyclics Revenue in Epigenetics Drugs and Diagnostic Technologies Business (2019-2024)
11.21.5 Pharmacyclics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock